Meet with... Correlation Ventures

Tuesday, April 15, 2014 from 10:30 AM to 12:30 PM (PDT)

Ticket Information

We are always looking for a few volunteers to assist with the event prep and registration one to two hours before the event starts. Following the registration, volunteers then attend the event just like the regular audience. Volunteers’ duties include: set up registration table, set up event package, registration assistance, hand-out name-tags, conduct onsite registration. We will personally follow up with you with all the details upon registration, so don't forget to indicate your email and phone number!

Event Details

Program Overview: Need a go/no go investment decision in two weeks or less? Want to meet a VC that is changing the venture investing paradigm? Then join us on April 15th to hear from David Coats, Managing Director at Correlation Ventures. David will provide an overview presentation of Correlation Ventures, discuss their unique funding process, and answer your funding questions.

Correlation Ventures aims to reduce the burden on Entrepreneurs when raising capital. Their proprietary approach allows for quick approvals when making U.S. venture co-investment decisions. They are actively making investments in 2014 and expect to make about 2 new investments a month throughout year. Correlation invests in all industry sectors and investment stages in private U.S.-headquartered companies. This includes life science, IT, etc., from seed to late stage investments. Click here for their portfolio.

Are you interested in the possibility to discuss your company directly with David? Then complete the online application by March 14th. Applications will be screened and all companies will be notified by March 25th whether your firm has been selected for a one-on-one meeting. Leaders from all areas of the life science industry are encouraged to apply today!

*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period ends March 14.APPLY HERE

About Correlation Ventures: Correlation Ventures is a new breed of venture capital firm, leveraging world-class analytics to offer entrepreneurs and other venture capitalists a dramatically better option when they are seeking additional capital to complete a financing round. Backed by leading institutional investors, Correlation has more than $165 million under management.

Fees:Presentation & Lunch Only$30 | General Public$40 | General Public OnsiteIncludes presentation, Q&A, and lunch. Registration to attend the presentation, Q&A, and lunch will remain open until April 14.

One-on-One MeetingIt is free to apply, but upon acceptance the following fees will apply:$25 | Accepted CompaniesIncludes one-on-one meeting only. Companies must have applied for a one-on-one meeting ahead of time. The application period ends on March 14. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Correlation Ventures Represenatatives:David Coats | Founder and Managing Director, Correlation VenturesAs a founder and Managing Director of Correlation Ventures, David helps lead the firm, including managing its Life Science and Clean Tech investment practices. David created the original vision for Correlation, driven by the opportunity to offer entrepreneurs and other VCs a better co-investment option and to pioneer the use of predictive analytics in venture capital. David began his venture capital career in 1997. Prior to Correlation, David was a Managing Director of Hamilton BioVentures, an early-stage venture capital fund. As head of Hamilton's Life Science team, David served on the Board of Directors of such companies as PhotoThera, Transcept (NASDAQ: TSPT), and Egea Biopharmaceuticals (Acquired by Johnson&Johnson). Previously, David was a Venture Partner at Windamere Venture Partners and President of Forge Medical Ventures, an early-stage incubator funded by Enterprise Partners, Mayfield Fund and Johnson & Johnson Development Corporation. David was the Founder of Spine Wave, a venture-funded medical device company and Director of Business Development of UroMed Corporation (URMD), a venture-funded startup that raised several rounds of venture capital and completed a public offering. David received an M.B.A. from the Harvard Graduate School of Business Administration and graduated Summa Cum Laude with a B.S. in Biology from Princeton University.

Alexa Fischer | Senior Associate, Correlation VenturesAlexa supports the firm’s sourcing, investment, and analytics activities. Prior to joining Correlation, Alexa worked as an Analyst at Harlingwood Equity Partners, where she performed industry research related to potential M&A, buyout, private placement, and investment opportunities. Previously, Alexa spent two years as a Business Litigation Legal Assistant at Luce, Forward, Hamilton & Scripps. Alexa holds an M.B.A. from San Diego State University, where she was named Outstanding Graduate Student of the Year by the Management Department, and a B.A. from The University of Michigan, where she graduated with Distinction.

About the Meet with... Series:The purpose of the Meet with Series events sponsored by Janssen Labs is to help start-up entrepreneurs as well as the academic community connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include: Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund and Thomas McNerney & Partners.

Tuesday, April 15, 2014 from 10:30 AM to 12:30 PM (PDT)

Organizer

JLABS Bay Area

JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas.

JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation, Inc. any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and Johnson & Johnson Innovation JLABS has now two established locations in San Francisco, one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility, and in Boston, through a collaboration with Lab Central. For more information please visit jlabs.jnjinnovation.com.